Xinnate AB partners with Destum Partners, Inc. to accelerate partnership activities for TCP-25 as treatment for EB

Nick Klock, partner and VP Business Development, Destum Partners Inc., and Helene Hartman, CEO, Xinnate AB

Lund, Sweden – Xinnate AB today announced a strategic collaboration with Destum Partners, Inc., a leading global, advisory firm specializing in the life sciences sector. Under the agreement, Destum Partners will act as the exclusive advisor to Xinnate AB for identifying and developing partnership opportunities for TCP-25 gel, the company’s innovative drug candidate for the treatment of Epidermolysis Bullosa (EB). EB is a group of rare, often very severe inflammatory disorders which causes fragile, blistering skin, resulting in recurring and chronic wounds.

“Following our positive Phase 1 data, including patients with Dystrophic EB, we sought the expertise of Destum Partners to support our mission of finding the right partner to advance TCP-25 gel and bring this much-needed treatment to patients,” said Helene Hartman, CEO of Xinnate AB. “With Destum Partners’ guidance, we are now ramping up our partnering activities, including introducing TCP-25 to potential strategic partners at the upcoming JP Morgan Healthcare Conference in January.”

“TCP-25 is an exciting drug candidate that has already attracted significant interest,” added Tom Filipczak, Managing Director and Partner at Destum Partners. “We are thrilled to collaborate with the Xinnate team and contribute to their efforts to unlock the full potential of TCP-25 through strategic partnerships.”

For more information
Helene Hartman, CEO of Xinnate AB
Helene.hartman@xinnate.com
Phone: +46 (0)72-512 03 12

About Xinnate AB
Xinnate AB is a clinical-stage pharmaceutical development company that develops novel, pharmaceutical therapies based on a pioneering technology of immune modulating peptides, that targets dysfunctional healing by controlling presence of microbes and the complex interplay of inflammatory responses. Xinnate AB runs an ambitious development program to transform lives for patients with high unmet medical need in inflammatory skin conditions, and complex wounds. A phase II-study of the company´s first drug candidate, TCP-25 gel, on Epidermolysis Bullosa is planned to start during 2025. Xinnate is a member of SmiLe Venture Hub at Medicon Village in Lund, Sweden.

About Destum Partners, Inc.
Destum Partners, Inc. (www.destumpartners.com) is a global, advisory and consultancy firm specializing in the biopharmaceutical and life sciences industries. For more than 18 years, Destum Partners has worked with clients ranging from large, multinational Fortune 500 companies through mid-sized/early-stage companies, globally completing transactions and providing customized market research and valuations. Destum Partners is therapeutically agnostic and has completed over USD $5.15B in deal value.